IDE 251
Alternative Names: IDE-251Latest Information Update: 08 Jan 2025
Price :
$50 *
At a glance
- Originator IDEAYA Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action KAT6A protein inhibitors; KAT6B protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Non-small cell lung cancer
Most Recent Events
- 16 Dec 2024 Preclinical trials in Breast cancer in USA (unspecified route)
- 16 Dec 2024 Preclinical trials in Non-small cell lung cancer in USA (unspecified route)
- 16 Dec 2024 IDEAYA Biosciences announces intention to submit an Investigational New Drug (IND) application to the US FDA for Breast cancer and Non-small cell lung cancer in 2025